Waukeshahealthinsurance.com-
–
Medicare in 2010 It will spend $5.7 billion on Ozympic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.
Cost-effective medicines that include Mounjaro and Rybelsus are becoming increasingly popular for diabetes treatment and weight loss. But Medicare is not allowed by law to cover weight loss drugs.
Medicare began covering Ozempic for people with diabetes in 2018, and Rybelsus and Mounjaro joined in 2019 and 2022, respectively. Medicare recently announced that it will cover WegoVin for people who are overweight or obese. Heart disease After the drug is found Approval Cardiovascular benefits from the US Food and Drug Administration.
The KFF study examined total cost, which does not take into account any rebates paid by drug manufacturers that reduce Medicare spending. Data on discount rates is not publicly available.
Ozempic ranks as the sixth best-selling drug in Medicare Part D drug plans in 2022, up from 10th last year, according to KFF. Medicare in 2010 It will spend $4.6 billion in 2022, compared to $2.6 billion previously. At this time List price A four-week supply of Ozempic is $969.
The drugs' popularity and price increase costs for the federal government and Medicare enrollees more broadly.
“These drugs offer significant health benefits, but the combination of high demand, new uses, and high prices for these treatments can put significant pressure on Medicare costs, Part D plan costs, and Part D coverage,” KFF wrote. By analyzing.
Although coverage of WeGoV and similar drugs could reduce other health care costs, these drugs at current prices still cost the federal government more than they save, according to a Congressional Budget Office analysis released last week.
Medicare may choose Ozempic and Rybelsus for him. Drug negotiation program In the year As early as 2025, KFF wrote, that would reduce the cost of the drugs.